Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So what’s the word did the listing fail again?
How so it was like this a week ago the bed actually went higher how is today’s price action anything special? you watch uplist will fail again because the company is incompetent.
No they’re not quit making stuff up so far the buyers for today are 190,000 in the sells are 144,000 according to Webull
Yeah, on the same platform it’s been trading on for the last three years so my point is obviously it’s not uplisting
You’re still saying that? But it’s supposed to be closing today doesn’t that mean we wouldn’t be able to trade it?
So they walk the bed up just enough for somebody to sell 100,000 shares and then it drops so typical
And it seems like once again, all these people don’t have a clue what they’re talking about. It’s almost as if their promoters not investors.
Isn’t this supposed to be uplifting today? Doesn’t look like it’s happening
Well, if they don’t, they’re screwed because the latest S1 said the principal payment on the loan was due by the 31 of January
And 2 transaction 900,000 shares were bought. It only brought it up at 10th of a cent but right after that 4000 shares were sold and it brought it down below where it was the stock is so manipulated and 900,000 shares should’ve brought it up a couple cents
Yeah, a binding misprint
Yeah, but that’s ridiculous. $400 a share is absurd. The fact that that’s even in the S1 suspect., that means all the investors would get screwed on that
I think I’m gonna try my best to contact Dr. Emily chew at the NEI and see if they really do have a research agreement
This paragraph is copy and pasted out of the S one
“As of the date hereof, there are 227,000 shares of Series B Preferred Stock outstanding. The Series B Preferred Stock is convertible, at the option of the holder into shares of Common Stock at $3.00 per share, or a total of 75,666 shares. The Series B Preferred stock also has the right to receive $400.00 per share upon a liquidation, dissolution or winding up in preference to the holders of Common Stock.”
In the newest S1 it said they moved the payment date of the principal to 31 January. that mean that the uplist reverse split and offering Hass to take place by the end of January or they default, on their convertible note, so that makes me feel the reason that they’ve kept price at two cents is so that people don’t sell because if people sell The value of the stock will plummet and they won’t have any capital left to cash in their series B preferred shares, that pay $400 per share
Why did they disclose half of that information last time none of the other S ones talked about the fact that if the company goes under the preferred B shares are worth $400. They’ve never talked about how much dilution and detail the stock was going to experience after the uplist they haven’t broken down a lot of the stuff they broke it down in this most recent S1, are they doing it to cover their ass because they think they’re going to go under
Have you seen all the new stuff they added to this S1 you claim that you’re an investor, but you don’t seem to be worried about it in the slightest, and I would think that some of the things in this newest update would be concerning to you if you were an investor? Do you think they’re just trying to scare people into selling and that’s why they put all this red flags all over this thing?
You seem to have pretty good insight and are knowledgeable about the stock and how things work I’m curious what you think of the latest S 1 and all the new information that’s been put out in it specifically the part where it talks about series be preferred shares being worth $400 a share as well as the dilution of $5.06 per share and what that actually means?
In December 2022, the Company sold 146,000 shares of Series B Preferred Stock for $146,000 and issued 19,048 shares of common stock upon the exercise of warrants, which resulted in $152,390 of cash proceeds
so in December they sold 146,000 shares of series B preferred stock which is worth $400 a share upon winding up or dissolving of company and now they’re talking about possibly not having funding past February as well
People need to read through everyone of my post to see what is in this S1 this newest test one basically states we have enough money to operate until February. If they default on the convertible note from March 2022, the warrant saw immediately exercisable if that doesn’t happen, the lender during the offering plans on selling their warrants, you know those 20 million and if the company winds up the series b preferred shares are worth $400 a share.
People need to read through this newest s1 things put in this one, the dark in the others like this, for instance
As of the date hereof, there are 227,000 shares of Series B Preferred Stock outstanding. The Series B Preferred Stock is convertible, at the option of the holder into shares of Common Stock at $3.00 per share, or a total of 75,666 shares. The Series B Preferred stock also has the right to receive $400.00 per share upon a liquidation, dissolution or winding up in preference to the holders of Common Stock. T
It says on the S one that they have $636 and only have funding until February. That’s not good.
Future funding does that mean another offering or reverse split? Read this
We anticipate that we will need approximately $38 million and a period of two (2) years to reach inflection points in all current indications underlying programs that we are actively pursuing. An inflection point, as used herein, is a point in product development where we believe we have enough significant value to reasonably expect to be able to partner out, license, and/or sell the program to an entity with the appetite and resources to take it to launch and commercialization. We will also require a substantial amount of additional funding to implement our other indications described in this prospectus under the caption “Business,” including our in-licensing strategy if such other programs are acquired. Although we believe the net proceeds from this offering will be sufficient to reach certain inflection points related to our current development plans, as applicable to the specific programs and indications, we do not believe it will be sufficient to receive FDA approval to market such products. Accordingly, we will need additional capital in the future.
financing. Our cash balance at September 30, 2022 was $636. Based on our current expected level of operating expenditures, we expect to be able to fund our operations until February of 2023.
185,770 shares of Common Stock issuable upon the exercise of outstanding warrants having an average weighted exercise price of $30.23. Notwithstanding, such amount of warrants will increase by 1,091,480 shares of Common Stock (assuming the $6.00 offering price and utilizing the 1-for-400 reverse stock split as set forth on the cover page of this Prospectus) underlying the warrant issued to the lender in our March 2022 convertible note offering pursuant to an adjustment feature in the number of shares underlying the warrant upon the consummation of an underwritten equity financing of the Company’s securities at a price per share in such offering that if multiplied by 75%, would be less than $20.00. The lender in our March 2022 convertible note offering has informed us and the underwriter that it plans on selling the warrants in a private sale to another accredited investor prior to or in conjunction with the closing of this offering;
Or that little bump in price last week was so that aegis could get a better deal open up at $8.80 and then they can immediately sell for $2.80 profit per share , any opinions on why the newest s1
Starting to wonder if they’re just going to keep filing S1 s until April and then they’ll say well. We were unable to get the S one done we no longer have any working capital to keep going so we’re going to dissolve the company. Meanwhile, they’ve sold millions of shares and will never be scrutinized once operations cease
So they changed it to an opening price of $8.80. They lowered the price down to 6.8 million and the buyers of the offering get it for 6.00 a share which means dilution even further
How many days is May 15? Wow what a joke.
Maybe maybe not you have no idea none of us do, but I’m looking at past performance
Management shouldn’t be making any more than 10 grand apiece per month for a total of around 30,000 a month and they need to put about 6 million into getting these drugs to market. They can start paying themselves extravagant salaries when they actually start making shareholder value.
Yeah, cause that seems normal for a company that has no income
What I mean is insiders are getting 8 million whether they piss away or they actually use it to do something for investors is a different story but is it possible that they know they’re getting that money so they’re not worried about that but yet still may be worried that the shares they hold might go down in value so they’re trying to offload them now?
Do you think that it’s insiders that know they’re getting $8 million in financing and so they’re wanting to get out as many shares as I can before the financing in fear that it will never recover??
Well on Webull it says the buys were 428,000 and the sells were 283,000 is that good or bad?
No that’s what you have or less. I actually have a few hundred thousand shares been sitting on them for two years 11 1/2 months.
I’ve been in the stock since February 2020 guy that’s three years oh you got me two years 11 1/2 months
Because apparently three years isn’t long enough to be patient
Uh huh ok
For once, I agree with you on this that should’ve been a long time ago and I feel like it all revolves around them wanting to stick to the 400 and one reverse, split and keep the price of .02.